NCT01298310

A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)

A Randomised, Double-blind, Placebo-controlled, Three-way Cross-over Single Center Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To characterize the phenotype in patients with Morton's neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Detailed description

A randomised, double-blind, placebo-controlled, three-way cross-over single center study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Conditions

• Morton's Neuroma

Interventions

Type	Name	Description
DRUG	Xylocaine	1 mg/mL solution for injection
DRUG	Xylocaine	10 mg/mL solution for injection
DRUG	Placebo	solution for injection

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2011-02-17
• Last updated: 2012-05-22

Locations

1 site across 1 country: Sweden